MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.